Microbot Medical® Files 10-Q, Reports Significant Revenue and Customer Growth During the 2026 Second Quarter
Microbot Medical filed its Q2 2026 Form 10-Q, reporting over 100% sequential growth in both revenue and customers driven by the Full Market Release of the LIBERTY System. Commercial expansion accelerated with new health system adoptions in four states, entry into federal healthcare via Lovell Government Services, and an expansion of sales territories from four to eight.
Key figures
- Sales territories
- 8
- Revenue growth qoq
- >100%
- Customer growth qoq
- >100%
- Sales territories target
- 12
- Government facilities access
- >2,000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.